Compare JNJ & PM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JNJ | PM |
|---|---|---|
| Founded | 1886 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.4B | 277.9B |
| IPO Year | 2003 | 2007 |
| Metric | JNJ | PM |
|---|---|---|
| Price | $259.78 | $185.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 9 |
| Target Price | ★ $238.20 | $189.78 |
| AVG Volume (30 Days) | ★ 7.7M | 5.1M |
| Earning Date | 04-14-2026 | 04-22-2026 |
| Dividend Yield | 2.36% | ★ 3.61% |
| EPS Growth | ★ 90.50 | 60.62 |
| EPS | ★ 4.41 | 3.36 |
| Revenue | N/A | ★ $40,648,000,000.00 |
| Revenue This Year | $6.63 | $10.54 |
| Revenue Next Year | $7.43 | $6.65 |
| P/E Ratio | $58.91 | ★ $55.42 |
| Revenue Growth | N/A | ★ 7.31 |
| 52 Week Low | $172.72 | $142.11 |
| 52 Week High | $274.90 | $207.76 |
| Indicator | JNJ | PM |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 46.54 |
| Support Level | $247.97 | $182.29 |
| Resistance Level | $272.16 | $190.25 |
| Average True Range (ATR) | 5.38 | 4.29 |
| MACD | -0.68 | -1.16 |
| Stochastic Oscillator | 25.31 | 6.29 |
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heat sticks, vapes, and oral nicotine offerings, primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI is not only dominant in smokable products but also has the Iqos and Zyn brands, which respectively dominate heated tobacco and nicotine pouches in most markets. It also owns the Veev brand in vapes.